Search research articles
Contact Us
Filters
Showing results (31-40 of 51) with videos related to
Page
of 6
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
August 24, 2018
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder
Dan J Stein, Jon-Paul Khoo, Antti Ahokas, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
June 5, 2026
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study"
Andreas Reif, A Elif Anıl Yağcıoğlu, Istvan Bitter, et al.
Trials
|
February 13, 2020
Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial
Gara Arteaga-Henríquez, Silvia Karina Rosales-Ortiz, Alejandro Arias-Vásquez, et al.
Schizophrenia (Heidelberg, Germany)
|
March 1, 2026
Persistent negative symptoms in the EULAST cohort: impact on functional outcome
Luigi Giuliani, Pasquale Pezzella, Giulia M Giordano, et al.
The New England Journal of Medicine
|
October 4, 2023
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Andreas Reif, Istvan Bitter, Jozefien Buyze, et al.
Frontiers in Psychiatry
|
February 21, 2022
Assessment and Treatment of Negative Symptoms in Schizophrenia-A Regional Perspective
Istvan Bitter, Pavel Mohr, Natalia Raspopova, et al.
The Lancet. Psychiatry
|
January 30, 2023
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)
Inge Winter-van Rossum, Mark Weiser, Silvana Galderisi, et al.
BMC Psychiatry
|
March 1, 2013
Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate
Michael Kluge, Ulrich Hegerl, Christian Sander, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
November 28, 2017
A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study)
Ulrich Hegerl, Roland Mergl, Christian Sander, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
February 16, 2026
Rethinking Schizophrenia: Optimizing Care Pathways in Europe from the First Episode of Psychosis to Long-Term Care
Pavel Mohr, Geert Dom, Peter Falkai, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 51) with videos related to
Sort By:
Page
of 6
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
August 24, 2018
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder
Dan J Stein, Jon-Paul Khoo, Antti Ahokas, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
June 5, 2026
Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study"
Andreas Reif, A Elif Anıl Yağcıoğlu, Istvan Bitter, et al.
Trials
|
February 13, 2020
Treating impulsivity with probiotics in adults (PROBIA): study protocol of a multicenter, double-blind, randomized, placebo-controlled trial
Gara Arteaga-Henríquez, Silvia Karina Rosales-Ortiz, Alejandro Arias-Vásquez, et al.
Schizophrenia (Heidelberg, Germany)
|
March 1, 2026
Persistent negative symptoms in the EULAST cohort: impact on functional outcome
Luigi Giuliani, Pasquale Pezzella, Giulia M Giordano, et al.
The New England Journal of Medicine
|
October 4, 2023
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Andreas Reif, Istvan Bitter, Jozefien Buyze, et al.
Frontiers in Psychiatry
|
February 21, 2022
Assessment and Treatment of Negative Symptoms in Schizophrenia-A Regional Perspective
Istvan Bitter, Pavel Mohr, Natalia Raspopova, et al.
The Lancet. Psychiatry
|
January 30, 2023
Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)
Inge Winter-van Rossum, Mark Weiser, Silvana Galderisi, et al.
BMC Psychiatry
|
March 1, 2013
Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate
Michael Kluge, Ulrich Hegerl, Christian Sander, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
November 28, 2017
A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study)
Ulrich Hegerl, Roland Mergl, Christian Sander, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
February 16, 2026
Rethinking Schizophrenia: Optimizing Care Pathways in Europe from the First Episode of Psychosis to Long-Term Care
Pavel Mohr, Geert Dom, Peter Falkai, et al.
Page
of 6